Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AADI NASDAQ:EGRX NASDAQ:FWP NYSE:OSTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAADIAadi Bioscience$1.75-2.2%$1.89$1.21▼$3.81$43.22M0.68261,100 shs51,924 shsEGRXEagle Pharmaceuticals$3.19-13.6%$2.88$1.50▼$3.87$41.43M0.837,380 shs675 shsFWPForward Pharma A/S$1.95$2.17$1.50▼$6.48$13.83M1.387,484 shsN/AOSTXOS Therapies$1.75-1.7%$1.75$1.12▼$7.00$49.17MN/A736,787 shs297,148 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAADIAadi Bioscience-2.23%-9.79%-5.91%+1.45%+12.90%EGRXEagle Pharmaceuticals-13.55%-13.55%+10.19%+61.93%-33.82%FWPForward Pharma A/S0.00%0.00%0.00%0.00%0.00%OSTXOS Therapies-1.69%-2.78%-8.38%-14.22%+174,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAADIAadi Bioscience0.4862 of 5 stars1.00.00.00.00.02.51.3EGRXEagle Pharmaceuticals1.9577 of 5 stars0.02.00.03.90.63.30.0FWPForward Pharma A/SN/AN/AN/AN/AN/AN/AN/AN/AOSTXOS Therapies2.0837 of 5 stars3.70.00.00.01.11.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAADIAadi Bioscience 2.00Hold$1.67-4.76% DownsideEGRXEagle Pharmaceuticals 0.00N/AN/AN/AFWPForward Pharma A/S 0.00N/AN/AN/AOSTXOS Therapies 3.40Buy$18.00928.57% UpsideCurrent Analyst Ratings BreakdownLatest FWP, OSTX, EGRX, and AADI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/14/2025OSTXOS TherapiesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.006/30/2025OSTXOS TherapiesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.006/24/2025OSTXOS TherapiesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.006/9/2025OSTXOS TherapiesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.005/15/2025OSTXOS TherapiesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.00(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAADIAadi Bioscience$25.07M1.72N/AN/A$4.29 per share0.41EGRXEagle Pharmaceuticals$257.55M0.16$7.98 per share0.40N/A∞FWPForward Pharma A/SN/AN/AN/AN/A$10.09 per shareN/AOSTXOS TherapiesN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAADIAadi Bioscience-$65.76M-$2.35N/AN/AN/A-246.06%-71.87%-57.28%8/5/2025 (Estimated)EGRXEagle Pharmaceuticals$35.64MN/A0.00∞N/AN/AN/AN/AN/AFWPForward Pharma A/S-$1.89MN/A0.00∞N/AN/AN/AN/AN/AOSTXOS Therapies-$7.79M-$0.86N/AN/AN/AN/AN/A-569.57%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAADIAadi BioscienceN/AN/AN/AN/AN/AEGRXEagle PharmaceuticalsN/AN/AN/AN/AN/AFWPForward Pharma A/SN/AN/AN/AN/AN/AOSTXOS TherapiesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAADIAadi BioscienceN/A4.894.54EGRXEagle PharmaceuticalsN/AN/AN/AFWPForward Pharma A/SN/A18.43N/AOSTXOS TherapiesN/A0.760.76Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAADIAadi Bioscience52.08%EGRXEagle Pharmaceuticals85.36%FWPForward Pharma A/S12.57%OSTXOS TherapiesN/AInsider OwnershipCompanyInsider OwnershipAADIAadi Bioscience37.30%EGRXEagle Pharmaceuticals28.90%FWPForward Pharma A/S71.47%OSTXOS Therapies13.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAADIAadi Bioscience4024.70 million15.49 millionOptionableEGRXEagle Pharmaceuticals10012.99 million9.23 millionNo DataFWPForward Pharma A/S47.09 million2.02 millionNot OptionableOSTXOS TherapiesN/A28.10 millionN/AN/AFWP, OSTX, EGRX, and AADI HeadlinesRecent News About These CompaniesContrasting OS Therapies (NYSE:OSTX) and Nuvo Pharmaceuticals (OTCMKTS:MRVFF)July 31 at 2:25 AM | americanbankingnews.comHead to Head Contrast: OS Therapies (OSTX) and The CompetitionJuly 24, 2025 | americanbankingnews.comOS Therapies Inc News (OSTX) - Investing.comJuly 18, 2025 | investing.comOS Therapies Inc. (NYSE-A: OSTX) Makes Important Strides in Rare Cancer TherapyJuly 14, 2025 | theglobeandmail.comOS Therapies Raises $4.2M Through Warrant ExerciseJuly 14, 2025 | tipranks.comOS Therapies Closes $4.2 Million in Warrant Exercise Inducement and Exchange OfferJuly 14, 2025 | newsfilecorp.comNOS Therapies Inc.: Promising Cancer Immunotherapy and Strategic Regulatory Advancements Support Buy RatingJuly 11, 2025 | tipranks.comOS Therapies Provides Clinical & Global Regulatory UpdatesJuly 10, 2025 | newsfilecorp.comNAnalysts Conflicted on These Healthcare Names: OS Therapies Incorporated (OSTX), Korro Bio (KRRO) and Veeva Systems (VEEV)July 3, 2025 | theglobeandmail.comOSTX - OS Therapies Inc Executives - MorningstarJuly 3, 2025 | morningstar.comMOS Therapies Granted End of Phase 2 Meeting by US FDA for OST-HER2 Program in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic OsteosarcomaJuly 3, 2025 | businesswire.comPositive Buy Rating for OS Therapies Driven by Promising Phase 2b Trial Results and Regulatory ProgressJuly 2, 2025 | tipranks.comOS Therapies Presents Statistically Significantly Positive 1-Year Event Free Survival, Overall Survival and Safety Clinical Data Updates for OST-HER2 at the MIB Agents Factor ...June 30, 2025 | finance.yahoo.comOS Therapies Presents Statistically Significantly Positive 1-Year Event Free Survival, Overall Survival and Safety Clinical Data Updates for OST-HER2 at the MIB Agents Factor Osteosarcoma ConferenceJune 30, 2025 | businesswire.comOS Therapies Stock Surges 12.4% After Positive FDA Feedback on OST-HER2June 24, 2025 | msn.comOS Therapies Receives Positive FDA Meeting Feedback on Regulatory Pathway for Accelerated Approval of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pediatric Lung Metastatic OsteosarcomaJune 24, 2025 | businesswire.comOS Therapies Announces Warrant Exercise Inducement & Exchange OfferJune 23, 2025 | businesswire.comOS Therapies Partners with EVERSANA for the U.S. Commercialization of OST-HER2 in Recurrent, Fully Resected, Pediatric Lung Metastatic OsteosarcomaJune 10, 2025 | prnewswire.comOSTX OS Therapies IncorporatedJune 1, 2025 | seekingalpha.comBuy Rating for OS Therapies: Promising Developments and Strategic Positioning in Cancer ImmunotherapyMay 21, 2025 | tipranks.comNew MarketBeat Followers Over TimeFWP, OSTX, EGRX, and AADI Company DescriptionsAadi Bioscience NASDAQ:AADI$1.75 -0.04 (-2.23%) As of 07/31/2025Aadi Bioscience, Inc., a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa. The company is also involved in evaluating FYARRO in cancers, including indications targeting specific genomic alterations that activate the mTOR pathway. Aadi Bioscience, Inc. was incorporated in 2007 and is headquartered in Pacific Palisades, California.Eagle Pharmaceuticals NASDAQ:EGRX$3.19 -0.50 (-13.55%) As of 08/1/2025 02:32 PM EasternEagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.Forward Pharma A/S NASDAQ:FWPForward Pharma A/S does not have significant operations. Previously, it operated as a biopharmaceutical company that focused on developing FP187 proprietary formulation of dimethyl fumarate for the treatment of inflammatory and neurological indications. Forward Pharma A/S was incorporated in 2005 and is headquartered in Copenhagen, Denmark.OS Therapies NYSE:OSTX$1.75 -0.03 (-1.69%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$1.76 +0.01 (+0.86%) As of 08/1/2025 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale AbbVie Stock Eyes Breakout as Pipeline and Profits Grow Why Bloom Energy Stock Could Break to New Highs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
